Research progress on clinical application and safety of GLP-1RA in children and teenagers with type 2 diabetes and obesity
In recent years,the incidence rate of type 2 diabetes(T2DM)and obesity in children and teenagers in China is increasing year by year.However,currently there are limited drugs approved domestically for the treat-ment of T2DM and obesity in children and teenagers,and the failure rate is high.In recent years,studies have shown that glucagon like peptide-1 receptor agonists(GLP-1RA)are effective and have good short-term safety in lowering blood sugar and weight loss in children and teenagers with T2DM and obese patients.However,chil-dren and teenagers in the growth and development stage have different reactions and tolerance levels to GLP-1RA compared to adults,and the incidence of gastrointestinal adverse reactions and hypoglycemia is significantly increased.Therefore,it is necessary to pay attention to the safety of their long-term use,and more systematic re-search and long-term follow-up evaluation should be further conducted.
glucagon like peptide-1 receptor agonistchildrenteenagerstype 2 diabetesobesity
国家科技期刊平台
NSTL
万方数据
